Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Rhinorrhea, cough and fatigue in patients taking sitagliptin. | Baraniuk and Jamieson Allergy Asthma Clinical Immunology 2010 6 8 http content 6 1 8 ALLERGY ASTHMA CLINICAL IMMUNOLOGY RESEARCH Open Access Rhinorrhea cough and fatigue in patients taking sitagliptin James N Baraniuk1 and Mary J Jamieson 2 Abstract Sitagliptin is a dipeptidyl peptidase-4 DPP IV CD26 inhibitor indicated for treatment of Type II diabetes as a second line therapy after metformin. We report fifteen sitagliptin intolerant patients who developed anterior and posterior rhinorrhea cough dyspnea and fatigue. Symptoms typically developed within 1 to 8 weeks of starting and resolved within 1 week of stopping the drug. Peak expiratory flow rates increased 34 in 8 patients who stopped sitagliptin. Similar changes were found in 4 out of 5 persons who had confirmatory readministration. Chart review identified 17 patients who tolerated sitagliptin and had no symptomatic changes. The sitagliptin intolerant group had higher rates of clinically diagnosed allergic rhinitis 15 15 vs. 6 18 p Fisher s Exact test and angiotensin converting enzyme inhibitor - induced cough 6 13 vs. 1 18 p . Nasal and inhaled glucocorticoids may control the underlying allergic inflammation and abrogate this new sitagliptin - induced pharmacological syndrome. Potential mucosal and central nervous system mechanisms include disruption of neuropeptides and or cytokines that rely on DPP IV for activation or inactivation and T cell dysfunction. Background Sitagliptin is a selective dipeptidylpeptidase-4 DPP IV CD26 EC inhibitor indicated for the treatment of Type II diabetes mellitus 1 . Diabetics treated with sitagliptin Januvia Merck Co. Inc. Whitehouse Station . develop upper respiratory tract infections cough and sore throat in 5 to 6 of subjects 2 . Similar rates for these adverse events have been reported for the other DPP IV inhibitors vidagliptin 3 and saxa-gliptin 4 . Infections from all causes had a 34 relative risk increase 95 confidence .
